Welcome!

News Feed Item

2013 Japanese Hospital Microbiology Testing Market

NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

2013 Japanese Hospital Microbiology Testing Market

http://www.reportlinker.com/p01083065/2013-Japanese-Hospital-Microbiolog...

This new report from Venture Planning Group contains 891 pages, 75 tables, and presents a comprehensive analysis of the Japanese hospital microbiology testing market, including:

·         Major issues pertaining to the Japanese hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.

·         Current scientific views on definition, epidemiology, and etiology of major infectious diseases and microorganisms.

·         Volume and sales forecasts for 80 microbiology tests performed in Japanese hospital laboratories.

·         Instrumentation technologies and feature comparison of leading analyzers.

·         Sales and market shares of leading suppliers.

·         Emerging diagnostic technologies and their potential market applications.

·         Product development opportunities.

·         Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

·         Business opportunities and strategic recommendations for suppliers.

Contains 891 pages and 75 tables

 

 

 

Table of Contents

 

Introduction

Worldwide Market and Technology Overview

A. Major Infectious Disease Tests

1. AIDS

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

2. Adenovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

d. Adeno-Associated Viruses(AAV)

3. Aeromonas

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

4. Anthrax/Bacillus Anthracis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

5. Arboviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

6. Babesiosis

a. Background

7. Bacillary Epithelioid Angiomatosis (BEA)

And Other Bartonella (Rochalimaea)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

8. Blastocystis Hominis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

9. Brucella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

10. Campylobacter

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

11. Candida

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

12. Chagas Disease

a. Background

13. Chancroid

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

14. Chlamydia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

15. Clostridium Difficile

a. Background

b. Diagnostic Tests

c. Drugs and Vaccines

16. Coronaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

17. Coxsackieviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

18. Creutzfeldt-Jakob's Disease

a. Background

b. Diagnostic Tests

c. Vaccines

19. Cryptosporidium Parvum

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

20. Cyclospora Cayetanensis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

21. Cytomegalovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

22. Ebola Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

23. E. Coli

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

24. EchoVirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

25. Encephalitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

26. Enteroviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

27. Epstein-Barr Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

28. Giardia Lamblia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

29. Gonorrhea

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

30. Granuloma Inguinale

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

31. Hantavirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

32. Helicobacter Pylori

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

33. Hepatitis

a. Background

b. Hepatitis A

c. Hepatitis B

d. Hepatitis C

e. Vaccines and Drugs

34. Herpes Simplex Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

35. Human Herpes Virus-6 (HHV-6)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

36. Influenza Viruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

37. Legionella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

38. Lyme Disease

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

39. Lymphogranuloma Venereum (LGV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

40. Malaria

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

41. Measles (Rubeola)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

42. Meningitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

43. Microsporidium

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

44. Mononucleosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

45. Mumps

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

46. Mycoplasma

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

47. Papillomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

48. Parvovirus B19

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

49. Pneumonia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

50. Polyomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

51. Pseudomonas Aeruginosa

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

52. Rabies

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

53. Respiratory Syncytial Virus (RSV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

54. RhinoViruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

55. RotaVirus (REOVIRUS)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

56. Rubella(MEASLES)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

57. Salmonellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

58. Septicemia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

59. Shigellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

60. Staphylococcus Aureus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

61. Streptococci

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

62. Syphilis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

63. Toxoplasmosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

64. Trichomonas Vaginalis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

65. Tuberculosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

66. Vibrio

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

67. West Nile Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

68. Yersina

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

B. Instrumentation Review of Leading Analyzers Marketed

by Abbott, Beckman Coulter/Danaher, BioMerieux,

Ortho-Clinical Diagnostics, Roche, Siemens, Tosoh,

Wallac and Other Suppliers

C. Emerging Diagnostic Technologies

1. Molecular Diagnostics

2. Monoclonal Antibodies

3. Immunoassays

4. Differential Light Scattering

5. Information Technology

6. Artificial Intelligence

7. Liposomes

8. Flow Cytometry

9. Chromatography

10. Diagnostic Imaging

11. Gel Microdroplets

12. Other

Japan

A. Executive Summary

B. Business Environment

C. Market Structure

D. Market Size, Growth and Major Suppliers

Major Product Development Opportunities

A. Instrumentation

B. Reagent Kits and Test Systems/Panels

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies for Decentralized

Testing Markets

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Assessments

- Abbott

- Affymetrix

- Beckman Coulter/Danaher

- Becton Dickinson

- bioMerieux

- Bio-Rad

- Cepheid

- Diamedix

- DiaSorin

- Eiken Chemical

- Enzo Biochem

- Fujirebio

- Gen-Probe

- Hologic

- ID Biomedical

- Innogenetics/Solvay

- Kreatech

- Life Technology

- Lonza

- Nanogen/Elitech

- Novartis Diagnostics

- Ortho-Clinical Diagnostics

- Qiagen

- Roche

- Scienion

- Sequenom

- SeraCare

- Siemens

- Takara Bio

- Thermo Fisher

- Wallac

- Wako

 

 

 

List of Tables

 

Major Companies Developing or Marketing AIDS Tests

Major Companies Developing or Marketing Adenovirus

Tests

Major Companies Developing or Marketing Bartonella

Tests

Major Companies Developing or Marketing

Campylobacter Tests

Major Companies Developing or Marketing Candida

Tests

Major Companies Developing or Marketing Chlamydia

Tests

Major Companies Developing or Marketing Clostridium

Tests

Major Companies Developing or Marketing Coronavirus

Tests

Major Companies Developing or Marketing Cryptosporidium

Tests

Major Companies Developing or Marketing CMV Tests

Major Companies Developing or Marketing Echovirus

Tests

Major Companies Developing or Marketing Enterovirus

Tests

Major Companies Developing or Marketing EBV Tests

Major Companies Developing or Marketing Giardia

Tests

Major Companies Developing or Marketing Gonorrhea

Tests

Major Companies Developing or Marketing Hantavirus

Tests

Major Companies Developing or Marketing Helicobacter

Pylori Tests

Major Companies Developing or Marketing Hepatitis

Tests

Major Companies Developing or Marketing Herpes

Tests

Major Companies Developing or Marketing Influenza

Tests

Major Companies Developing or Marketing Legionella

Tests

Major Companies Developing or Marketing Lyme Disease

Tests

Major Companies Developing or Marketing Lymphogranuloma

Tests

Major Companies Developing or Marketing Malaria

Tests

Major Companies Developing or Marketing Measles

Tests

Major Companies Developing or Marketing Meningitis

Tests

Major Companies Developing or Marketing Microsporidium

Tests

Major Companies Developing or Marketing

Mononucleosis Tests

Major Companies Developing or Marketing Mumps Tests

Major Companies Developing or Marketing Mycoplasma

Tests

Major Companies Developing or Marketing Papilloma

Virus Tests

Major Companies Developing or Marketing Parvovirus

Tests

Major Companies Developing or Marketing Pneumonia

Tests

Major Companies Developing or Marketing RSV Tests

Major Companies Developing or Marketing Rotavirus

Tests

Major Companies Developing or Marketing Rubella

Tests

Major Companies Developing or Marketing Salmonella

Tests

Major Companies Developing or Marketing Septicemia

Tests

Major Companies Developing or Marketing Shigella

Tests

Major Companies Developing or Marketing Staphylococci

Tests

Major Companies Developing or Marketing

Streptococci Tests

Major Companies Developing or Marketing Syphilis

Tests

Major Companies Developing or Marketing Toxoplasmosis

Tests

Major Companies Developing or Marketing Trichomonas

Tests

Major Companies Developing or Marketing Tuberculosis

Tests

Major Companies Developing or Marketing West Nile

Tests

Major Companies Developing or Marketing Yersinia Tests

Japan Summary Table

All Infectious Diseases Test Volume and Diagnostics

Sales Forecast by Market Segment

Japan

Hospital Laboratories Performing Infectious Disease

Tests by Bed Size

Japan

Hospital Laboratories Infectious Disease Test

Volume Forecast

Japan

Hospital Laboratories Infectious Disease Diagnostics

Market Forecast

Japan

AIDS Testing Market Diagnostics Sales

by Major Supplier

Japan

Campylobacter Testing Market Diagnostics Sales

by Major Supplier

Japan

Candida Testing Market Diagnostics Sales

by Major Supplier

Japan

Chlamydia Testing Market Diagnostics Sales

by Major Supplier

Japan

CMV Testing Market Diagnostics Sales

by Major Supplier

Japan

Gonorrhea Testing Market Diagnostics Sales

by Major Supplier

Japan

Hepatitis Testing Market Diagnostics Sales

by Major Supplier

Japan

Hepatitis C Testing Market Diagnostics Sales

by Major Supplier

Japan

Herpes Testing Market Diagnostics Sales

by Major Supplier

Japan

Legionella Testing Market Diagnostics Sales Forecast

by Major Supplier

Japan

Meningitis Testing Market Diagnostics Sales

by Major Supplier

Japan

Mononucleosis Testing Market Diagnostics Sales

by Major Supplier

Japan

Mycoplasma Testing Market Diagnostics Sales

by Major Supplier

Japan

Pneumonia Testing Market Diagnostics Sales

by Major Supplier

Japan

RSV Testing Market Diagnostics Sales by Major Supplier

Japan

Rotavirus Testing Market Diagnostics Sales

by Major Supplier

Japan

Rubella Testing Market Diagnostics Sales

by Major Supplier

Japan

Septicemia Testing Market Diagnostics Sales

by Major Supplier

Japan

Shigella Testing Market Diagnostics Sales

by Major Supplier

Japan

Streptococci Testing Market Diagnostics Sales

by Major Supplier

Japan

Syphilis Testing Market Diagnostics Sales

by Major Supplier

Japan

Toxoplasmosis Testing Market Diagnostics Sales

by Major Supplier

Japan

Trichomonas Testing Market Diagnostics Sales

by Major Supplier

Japan

Tuberculosis Testing Market Diagnostics Sales

by Major Supplier

 

 

 

To order this report:

In_Vitro_Diagnostic Industry: 2013 Japanese Hospital Microbiology Testing Market

 

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Onalytica. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effici...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Regulatory requirements exist to promote the controlled sharing of information, while protecting the privacy and/or security of the information. Regulations for each type of information have their own set of rules, policies, and guidelines. Cloud Service Providers (CSP) are faced with increasing demand for services at decreasing prices. Demonstrating and maintaining compliance with regulations is a nontrivial task and doing so against numerous sets of regulatory requirements can be daunting task...
Successful digital transformation requires new organizational competencies and capabilities. Research tells us that the biggest impediment to successful transformation is human; consequently, the biggest enabler is a properly skilled and empowered workforce. In the digital age, new individual and collective competencies are required. In his session at 19th Cloud Expo, Bob Newhouse, CEO and founder of Agilitiv, drew together recent research and lessons learned from emerging and established compa...